BACKGROUND: Visceral pain is an important and prevalent clinical condition whose treatment is challenging. Sigma-1 (σ1) receptors modulate somatic pain, but their involvement in pure visceral pain is unexplored. METHODS: The authors evaluated the role of σ1 receptors in intracolonic capsaicin-induced visceral pain (pain-related behaviors and referred mechanical hyperalgesia to the abdominal wall) using wild-type (WT) (n = 12 per group) and σ1 receptor knockout (σ1-KO) (n = 10 per group) mice, selective σ1 receptor antagonists (BD-1063, S1RA, and NE-100), and control drugs (morphine and ketoprofen). RESULTS: The intracolonic administration of capsaicin (0.01-1%) induced concentration-dependent visceral pain-related behaviors and referred hyperalgesia in both WT and σ1-KO mice. However, the maximum number of pain-related behaviors induced by 1% capsaicin in σ1-KO mice (mean ± SEM, 22 ± 2.9) was 48% of that observed in WT animals (46 ± 4.2). Subcutaneous administration of the σ1 receptor antagonists BD-1063 (16-64 mg/kg), S1RA (32-128 mg/kg), and NE-100 (8-64 mg/kg) dose-dependently reduced the number of behavioral responses (by 53, 62, and 58%, respectively) and reversed the referred hyperalgesia to mechanical control threshold (0.53 ± 0.05 g) in WT mice. In contrast, these drugs produced no change in σ1-KO mice. Thus, the effects of these drugs are specifically mediated by σ1 receptors. Morphine produced an inhibition of capsaicin-induced visceral pain in WT and σ1-KO mice, whereas ketoprofen had no effect in either mouse type. CONCLUSION: These results suggest that σ1 receptors play a role in the mechanisms underlying capsaicin-induced visceral pain and raise novel perspectives for their potential therapeutic value.
BACKGROUND:Visceral pain is an important and prevalent clinical condition whose treatment is challenging. Sigma-1 (σ1) receptors modulate somatic pain, but their involvement in pure visceral pain is unexplored. METHODS: The authors evaluated the role of σ1 receptors in intracolonic capsaicin-induced visceral pain (pain-related behaviors and referred mechanical hyperalgesia to the abdominal wall) using wild-type (WT) (n = 12 per group) and σ1 receptor knockout (σ1-KO) (n = 10 per group) mice, selective σ1 receptor antagonists (BD-1063, S1RA, and NE-100), and control drugs (morphine and ketoprofen). RESULTS: The intracolonic administration of capsaicin (0.01-1%) induced concentration-dependent visceral pain-related behaviors and referred hyperalgesia in both WT and σ1-KO mice. However, the maximum number of pain-related behaviors induced by 1% capsaicin in σ1-KO mice (mean ± SEM, 22 ± 2.9) was 48% of that observed in WT animals (46 ± 4.2). Subcutaneous administration of the σ1 receptor antagonists BD-1063 (16-64 mg/kg), S1RA (32-128 mg/kg), and NE-100 (8-64 mg/kg) dose-dependently reduced the number of behavioral responses (by 53, 62, and 58%, respectively) and reversed the referred hyperalgesia to mechanical control threshold (0.53 ± 0.05 g) in WT mice. In contrast, these drugs produced no change in σ1-KO mice. Thus, the effects of these drugs are specifically mediated by σ1 receptors. Morphine produced an inhibition of capsaicin-induced visceral pain in WT and σ1-KO mice, whereas ketoprofen had no effect in either mouse type. CONCLUSION: These results suggest that σ1 receptors play a role in the mechanisms underlying capsaicin-induced visceral pain and raise novel perspectives for their potential therapeutic value.
Authors: M A Tejada; A Montilla-García; C Sánchez-Fernández; J M Entrena; G Perazzoli; J M Baeyens; E J Cobos Journal: Psychopharmacology (Berl) Date: 2014-03-18 Impact factor: 4.530
Authors: James R F Hockley; Rafael González-Cano; Sheridan McMurray; Miguel A Tejada-Giraldez; Cian McGuire; Antonio Torres; Anna L Wilbrey; Vincent Cibert-Goton; Francisco R Nieto; Thomas Pitcher; Charles H Knowles; José Manuel Baeyens; John N Wood; Wendy J Winchester; David C Bulmer; Cruz Miguel Cendán; Gordon McMurray Journal: J Physiol Date: 2017-03-01 Impact factor: 5.182
Authors: Mireia Carcolé; Sami Kummer; Leonor Gonçalves; Daniel Zamanillo; Manuel Merlos; Anthony H Dickenson; Begoña Fernández-Pastor; David Cabañero; Rafael Maldonado Journal: Br J Pharmacol Date: 2019-09-12 Impact factor: 8.739
Authors: Rohit Bhat; James A Fishback; Rae R Matsumoto; Jacques H Poupaert; Christopher R McCurdy Journal: Bioorg Med Chem Lett Date: 2013-06-29 Impact factor: 2.823
Authors: J M Entrena; C Sánchez-Fernández; F R Nieto; R González-Cano; S Yeste; E J Cobos; J M Baeyens Journal: Sci Rep Date: 2016-11-25 Impact factor: 4.379
Authors: Rafael González-Cano; Miguel Ángel Tejada; Antonia Artacho-Cordón; Francisco Rafael Nieto; José Manuel Entrena; John N Wood; Cruz Miguel Cendán Journal: Mar Drugs Date: 2017-06-21 Impact factor: 5.118
Authors: Sema G Quadir; Sean M Tanino; Yasmine N Sami; Margaret A Minnig; Malliga R Iyer; Kenner C Rice; Pietro Cottone; Valentina Sabino Journal: Alcohol Clin Exp Res Date: 2021-07-05 Impact factor: 3.928
Authors: Francisco R Nieto; Cruz M Cendán; Francisco J Cañizares; María A Cubero; José M Vela; Eduardo Fernández-Segura; José M Baeyens Journal: Mol Pain Date: 2014-02-11 Impact factor: 3.395